Results 171 to 180 of about 67,431 (260)

Complementary efficacy of CD127‐directed immunotherapy with lusvertikimab and ABL‐targeting tyrosine kinase inhibitors in preclinical ABL‐class‐fusion‐positive B‐ALL

HemaSphere, Volume 10, Issue 6, June 2026.
Denis Pinkle, Melissa Cornils, Anna Dietterle, Anna Laqua, Michelle Kurschies, Julia Heymann, Emily Funke, Philipp Fanter, Dennis D. Gupta, Claas Reimer, Denny Takudzwa Mahachi, Carina L. Gehlert, Dorothee Winterberg, Michaela Vossen‐Gajcy, Xenia Müller, Greta Balow, Katharina Iben, Malwine Barz, Lorenz Bastian, Claudia Baldus, Maja Kowol, Sally Kikvadze, Alexander A. Wurm, Ekaterina Logvinova, Christian Vokuhl, Jan P. Schmid, Irmela Jeremias, Katja Klausz, Matthias Peipp, Martin Schrappe, Irène Baccelli, Nicolas Poirier, Monika Brüggemann, Gunnar Cario, Denis M. Schewe, Lennart Lenk   +35 more
wiley   +1 more source

The Aging Microenvironment Shapes Angiogenic Remodeling in IBD‐Associated Colorectal Carcinogenesis

Aging Cell, Volume 25, Issue 6, June 2026.
In IBD, chronic inflammation promotes cellular senescence across epithelial, stromal, endothelial, and immune compartments. The resulting SASP drives pathological angiogenesis, vascular dysfunction, hypoxia, and immune suppression, thereby facilitating progression from inflammation to dysplasia and colitis‐associated colorectal cancer.
Ruoshu Duan, Qingyu Chen, Yuan Xu, Ye Yan, Sujing Jiang   +4 more
wiley   +1 more source

Simulation of Imatinib Pharmacokinetics in pregnant women with chronic myeloid leukemia in the third trimester. [PDF]

Eur J Clin Pharmacol
Mian P, Lok CAR, Dontje AEWK, Prins JR, Oude Munnink TH, Nieuwenhuizen L, Gordijn SJ, Touw DJ, Malik P.   +8 more
europepmc   +1 more source

Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data

Sandra Michiels,1– 3 Sandra Tricas-Sauras,2 Adriano Salaroli,3 Dominique Bron,3 Philippe Lewalle,3 Katrijn Vanschoenbeek,4 Hélène A Poirel,4 Fati Kirakoya-Samadoulougou1 1Center for Research in Epidemiology, Biostatistics and Clinical Research, School of
Michiels S, Lewalle P, Poirel HA, Bron D, Kirakoya-Samadoulougou F, Tricas-Sauras S, Vanschoenbeek K, Salaroli A   +7 more
core  

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Successful Management of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia in Chronic Phase Chronic Myeloid Leukemia with Ponatinib: A Case Report and Literature Review. [PDF]

Clin Med Insights Case Rep
Ghasoub R, Shafei L, Taha RY, Soliman D, Elsabah H, Benkharda M, Albattah A, Elomri H.   +7 more
europepmc   +1 more source

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies

European Journal of Haematology, Volume 116, Issue 6, Page 907-914, June 2026.
ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple, Katja Gall, Luisa Paschke, Hans‐Jochem Kolb, Angela Wawer, Hans Knabe, Irene von Luettichau, Julia Hauer, Uwe Thiel   +8 more
wiley   +1 more source

Impact of the changes in chronic myeloid leukemia classification proposed by the 2022 World Health Organization: a single-center Brazilian study. [PDF]

Hematol Transfus Cell Ther
Emiliano EG, Santos GEAA, Miranda ECM, Duarte GBO, Amarante GBD, De Souza CA, Pagnano KBB.   +6 more
europepmc   +1 more source

Diagnosing Systemic Mastocytosis: State of the Art

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 551-560, June 2026.
ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley   +1 more source

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions. [PDF]

Drug Des Devel Ther
Wang XD, Shou CH, Chen SC, Hong YY, Zhu KK, Yang WL, Yu JR.   +6 more
europepmc   +1 more source